6 pm News Flash – September 28, 2025

Controversy erupts before Asia Cup final

US proposes 21-point plan to end Gaza war; no governance role for Hamas

Mohun Bagan pull out of ACL 2 away match over security concerns

Disclaimer: This image is entirely AI-generated and is a product of artificial intelligence. Any resemblance to actual persons, whether living or deceased, is purely coincidental and unintentional.

Uploaded 4 hours ago

Duration: 0h 3m 30s

US tariffs: Only Sun Pharma exposed to some headline risk

Name: US tariffs: Only Sun Pharma exposed to some headline risk
Uploaded: Sun, 28 Sep 2025 14:14:58 +0530
Channel: Rediff Video Desk

The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report.

Uploaded by: Rediff Video Desk on Sun, 28 Sep 2025 14:14:58 +0530

Views: 9

Tags: US tariffs: Only Sun Pharma exposed to some headline risk

Share: